Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II entrectinib study in ROS1-rearranged advanced non-small-cell lung cancer detected by liquid biopsy
jRCT2031210004Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate by independent radiology review. Started Dec 2020; status: completed.
02
Drugs
entrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210004.